FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.
|Articles|August 20, 2014
- Immunotherapy (Issue 3)
- Volume 3
- Issue 1
Combining Immunotherapies With Targeted Therapies and Other Immunotherapies
Author(s)Gregory A. Daniels, MD, PhD
Gregory A. Daniels, MD, PhD, discusses opportunities to combine immunotherapies with both targeted therapies and other immunotherapies.
Advertisement
Gregory A. Daniels, MD, PhD, associate clinical professor of medicine, Division of Hematology-Oncology, University of California, San Diego, discusses opportunities to combine immunotherapies with both targeted therapies and other immunotherapies. Daniels references the results of the 2007-2012 PROCLAIM National Registry, which was presented at the 2014 ASCO Annual Meeting.
Read about combining immunotherapies > >
Articles in this issue
about 12 years ago
A Brief History of Immunotherapyabout 12 years ago
Better Biomarker Testing Needed in Immuno-Oncologyabout 12 years ago
Autoimmunity and Limitations of Cancer Vaccinesabout 12 years ago
The Management of Side Effects Associated With Immunotherapiesabout 12 years ago
The Next Wave in Immunotherapy: Combinationsabout 12 years ago
Future Immune Checkpoint StrategiesAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5